AI Science Tracker
EN

AI-assisted CT risk score retains mortality discrimination in a later COVID-19 cohort

Vita-Salute San Raffaele University; IRCCS San Raffaele Scientific Institute · 29 Aug 2022 · biology

Discovery

AI-assisted CT risk score retains mortality discrimination in a later COVID-19 cohort

Source check: Source checked. Not independent scientific confirmation.

Finding: A five-variable model combining demographic data, oxygen saturation and automatically extracted CT measurements distinguished recorded mortality in a later COVID-19 cohort. Developed from 1,125 first-wave patients, AI-SCoRE achieved a reported AUC of 0.808 in 213 second-wave patients. This supports a bounded clinical prognostic validation, without demonstrated treatment benefit or proof that the predictor was locked before validation outcomes accrued.

Technology: Pretrained U-Net lung segmentation with quantitative CT feature extraction, logistic risk modeling and CART risk binning

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Pretrained neural segmentation converted patient CT scans into quantitative lung features used with clinical variables in the represented mortality score; learned risk modeling and binning enabled the patient-outcome discrimination analysis.
Test and result
A multicenter first-wave dataset was reduced from 1,575 enrolled patients to 1,125 complete records, including 292 deaths. Repeated train/test splits and repeated cross-validation compared candidate models and selected a five-variable logistic model. Pretrained learned segmentation enabled automated lung measurements. A later, prospectively collected single-center cohort of 213 patients, including 31 deaths, yielded AUC 0.808 with reported 95% confidence interval 0.740–0.877.
Limitation / still unknown
Prospective cohort collection does not establish that the model and thresholds were fixed before its outcomes were known. Complete-case selection, different pandemic waves, one-center later validation and historical treatment conditions limit transportability. The paper inconsistently describes 213 versus 214 validation patients and presents four low-risk deaths as 1.8% without a clearly appropriate low-risk denominator; those percentages and post-hoc exclusions are not adopted here. Supplemental acquisition/endpoint details were not independently read. No causal CT mechanism, intervention benefit or current clinical utility is established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9423702/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Read primary front identity/date, clinical study design, modeling and segmentation Methods, cohort/model/later-wave mortality Results and limitations. Supplemental Methods were not independently read. Later cohort collection was prospective; temporal predictor locking was not established. Exact original article front DOI/title and fresh PubMed primary relationship metadata checked..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse biology discoveries.